Neurology | Phase I Developments | UNITED STATES

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer

Lead Product(s): PF-05251749

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Biogen

Deal Size: $710.0 million Upfront Cash: $75.0 million

Deal Type: Acquisition January 13, 2020

Details:

With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.

BrainStorm Cell Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for AZ

Lead Product(s): MSC-NTF cells

Therapeutic Area: Neurology Product Name: NurOwn

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

As part of the newly announced program, the Company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer's disease.

Atara Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Atara Biotherapeutics Enrolled First Patient in Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of M.S

Lead Product(s): ATA188

Therapeutic Area: Neurology Product Name: ATA188

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

Based on the Phase 1a study findings showing sustained disability improvements in active MS patients, the Phase 1b study will assess clinical outcomes including disability measures, physical and cognitive performance, biomarkers and MRI imaging, as well as safety.

Athira Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Athira Pharma Closes $85 Million Series B Financing

Lead Product(s): NDX-1017

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Perceptive Advisors

Deal Size: $85.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing June 04, 2020

Details:

The funding supports the company to advance its lead therapeutic candidate, NDX-1017, into Phase 2/3 clinical development and explore the potential of their pipeline of compounds across a range of central and peripheral neurodegenerative and neuropsychiatric indications.

Athira Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Athira Pharma to Present at Jefferies Virtual Global Healthcare Conference

Lead Product(s): NDX-1017

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Athira will present on the current state of the company and the advancement of lead therapeutic candidate, NDX-1017, for Alzheimer’s disease as well as pipeline development for other disease indications.

Anavex Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)

Lead Product(s): Anavex 3-71

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Anavex got approval from Australian Human Research Ethics Committee has to initiate the First-in-Human FIH clinical study of ANAVEX®3-71 (AF710B), a small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.

Atara Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 and EAN Virtual Congress

Lead Product(s): ATA188

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

Details:

Company will present updated safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking e-poster presentation at the 6th European Academy of Neurology (EAN) Annual Congress.

Linical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Linical and Alpha Cognition Announce Strategic Partnership to Position Alpha-1062 for Approval in the U.S and Japan Alzheimer's Markets

Lead Product(s): Alpha-1062

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Alpha Cognition

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership April 21, 2020

Details:

Under this agreement, Linical will provide strategic consulting services and regulatory guidance for Alpha-1062, a new chemical entity aimed to penetrate the Alzheimer's disease market.